Geniemed Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 100.24%
- Profit Growth 280.09%
- Ebitda 141.53%
- Net Worth 232.85%
- Total Assets 87.18%
About Geniemed
Geniemed Private Limited (GPL) is a Private Limited Indian Non-Government Company incorporated in India on 29 May 2018 (Six years and nine months 1 days old ). Its registered office is in Pune, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Gogula Vishnu, Srinu Bedadha, Bhagyalakshmi Malekati, and One other member serve as directors at the Company.
Company Details
- Location
Pune, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999PN2018PTC176905
- Company No.
176905
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 May 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Pharma
Who are the key members and board of directors at Geniemed?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gogula Vishnu  | Director | 29-May-2018 | Current |
| Srinu Bedadha | Director | 29-May-2018 | Current |
| Bhagyalakshmi Malekati | Director | 29-May-2018 | Current |
| Suchitra Kurati | Director | 18-Mar-2021 | Current |
Financial Performance of Geniemed.
Geniemed Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 100.24% increase. The company also saw a substantial improvement in profitability, with a 280.09% increase in profit. The company's net worth Soared by an impressive increase of 232.85%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Geniemed?
Unlock access to Geniemed's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Geniemed?
Geniemed has a workforce of 18 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Geniemed, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Geniemed's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.